Physician profile
Brian C Moraes
NPI 1417908823
$27,719.79
in general payments reported to CMS, 2019-2025
63 companies · $2,515 in 2025
The $2,515 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,834 · 2020: $2,361 · 2021: $5,245 · 2022: $6,502 · 2023: $4,836 · 2024: $2,426 · 2025: $2,515.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,777.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,777.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,806.79 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $3,186.45 | 2021-2025 | |
| Novo Nordisk INC | $3,073.47 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $2,553.62 | 2019-2025 | |
| Lilly USA, LLC | $1,771.00 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,664.31 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $1,624.59 | 2019-2023 | Spravato |
| Amgen INC. | $887.69 | 2019-2025 | Repatha, Prolia, Repatha |
| Glaxosmithkline, LLC. | $833.50 | 2020-2023 | Arexvy, Shingrix, Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $776.08 | 2019-2025 | Xifaxan, Trulance |
| Amarin Pharma, INC. | $634.61 | 2019-2022 | |
| Heartflow, INC. | $605.29 | 2022-2025 | |
| Pfizer INC. | $537.14 | 2020-2025 | |
| Sanofi-Aventis U.S. LLC | $451.88 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $416.31 | 2019-2025 |
Show all 63 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $405.88 | 2020-2025 | Nexletol |
| Allergan, INC. | $258.80 | 2019-2020 | |
| Corcept Therapeutics | $238.42 | 2021-2025 | Korlym |
| Radius Health, INC. | $232.51 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $206.11 | 2022-2024 | Quviviq |
| Exact Sciences Corporation | $200.24 | 2023-2025 | Cologuard Collection Kit |
| Almirall LLC | $185.28 | 2019-2022 | |
| Boston Scientific Corporation | $184.34 | 2022-2023 | Watchman Flx, Watchman Access System |
| Teva Pharmaceuticals USA, INC. | $169.14 | 2020-2021 | |
| Abbott Laboratories | $168.78 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Shield Therapeutics INC | $168.44 | 2023-2025 | Accrufer |
| Kowa Pharmaceuticals America, INC. | $166.47 | 2019-2021 | |
| Horizon Therapeutics Plc | $151.70 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $145.39 | 2021 | |
| Mannkind Corporation | $141.64 | 2021-2022 | |
| Astellas Pharma US INC | $140.38 | 2024-2025 | Veozah |
| Regeneron Healthcare Solutions, INC. | $134.19 | 2019 | |
| Lundbeck LLC | $128.31 | 2020-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $125.72 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $122.57 | 2022 | |
| Merck Sharp & Dohme LLC | $119.18 | 2021-2025 | Gardasil 9, Capvaxive |
| Axsome Therapeutics, INC. | $115.81 | 2025 | Symbravo |
| Stryker Corporation | $107.58 | 2025 | Omnicurve, Mild Device Kit, Optablate |
| Gilead Sciences, INC. | $100.00 | 2021 | |
| Cvrx, INC. | $91.05 | 2023-2024 | Barostim Neo System |
| Eisai INC. | $79.85 | 2020-2022 | |
| Acella Pharmaceuticals, LLC | $49.61 | 2019-2022 | |
| Arbor Pharmaceuticals, INC. | $48.84 | 2019-2021 | |
| Alkermes, INC. | $47.39 | 2025 | Vivitrol |
| Nestle Healthcare Nutrition INC. | $42.90 | 2022-2023 | |
| Biofrontera INC. | $42.52 | 2019-2021 | |
| Zyla Life Sciences, INC. | $41.40 | 2019 | |
| Regeneron Pharmaceuticals, INC. | $40.35 | 2019 | |
| Saluda Medical Americas, INC. | $30.07 | 2025 | Evoke |
| Halozyme INC | $29.91 | 2023 | |
| Cleerly, INC. | $27.70 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Medtronic, INC. | $22.44 | 2021 | |
| Genentech USA, INC. | $21.33 | 2021 | |
| Agepha Pharma Fz LLC | $20.17 | 2024 | Lodoco |
| Dexcom, INC. | $19.51 | 2024 | Dexcom G6 Transmitter |
| Corium, LLC | $19.25 | 2023 | Azstarys |
| Sunovion Pharmaceuticals INC. | $19.04 | 2019 | |
| Azurity Pharmaceuticals, INC. | $17.34 | 2023 | Edarbi |
| Galderma Laboratories, L.P. | $15.38 | 2019 | |
| Currax Pharmaceuticals LLC | $15.09 | 2023 | Contrave |
| Incyte Corporation | $15.00 | 2021 | |
| Therapeuticsmd, INC. | $13.05 | 2019 | |
| Pierre Fabre Pharmaceuticals, INC. | $10.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Moraes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.